112889-71-1

Upstream product

• 6714-68-7 spiro[1,3-dioxolane-2,3'-indolin]-2'-one 
• 60789-54-0 4-bromobutyl benzyl ether 
• 37647-71-5 3,4-dihydro-3,3-dimethylpyrimido[1,2-a]indole-10(2H)-one 
• 37647-56-6 2,2-dimethyl-3-<1'-<2'(1'H)-oxospiro<1,3-dioxolane-2,3'-indol>yl>>propanenitrile 
• 37647-57-7 C₁₅H₁₈N₂O₂ 
• 91-56-5 indole-2,3-dione 

Relevant academic research and scientific papers

Oral Hypoglycemic Agents. Pyrimidoindoles and Related Compounds

A series of pyrimidoindoles were synthesized and studied for their hypoglycemic activity following oral administration at standard dose of 100 mg/kg to fed rats.The effect of 10-alkoxyalkyl, 10-alkyl, 10-aryl, and 3,3-dialkyl substitution on the activity of 10-hydroxypyrimidoindoles was investigated.Relative potencies of a number of the most active compounds were defined by three-point dose-response studies.The most potent compounds were those with either 3,3-dimethyl substituents, compounds 21, 22, and 38, or 3,3-spirocyclohexane substituents, compounds 39 and 49. 10-Aminopyrimidoindoles were in general less active than the 10-hydroxy analogues, and potency was further decreased by derivatizing the 10-amino group.The most potent 10-amino derivatives were 57 and 58.

Pyrimidoindoles useful as hypoglycaemics

Compounds of formula STR1 wherein A represents a lower alkylene chain optionally containing one double or triple bond, RO represents (lower)alkoxy, aryl(lower)alkoxy, hydroxy or protected hydroxy, R1 and R2 which may be the same or d